Piper Sandler reiterates Overweight rating on Amgen stock after cancer drug success

Amgen (AMGN) reported positive top-line Phase III results for its gastric cancer treatment bemarituzumab, demonstrating statistically significant overall survival improvement, which led Piper Sandler to reiterate an Overweight rating and $328 price target, citing strong oncology growth potential. Concurrently, its obesity treatment candidate MariTide showed promising Phase 2 efficacy with up to 20% average weight loss, though market reaction was mixed due to competitive landscape concerns. These developments highlight Amgen's strategic efforts to expand its portfolio and strengthen market position, despite some noted ocular adverse events with bemarituzumab.

Analysis

Amgen is demonstrating significant progress in its clinical pipeline, particularly within its oncology franchise. The successful top-line results from the FORTITUDE-101 Phase III study for bemarituzumab, which met its primary endpoint of improving overall survival in gastric cancer patients, represent a material positive development. This prompted Piper Sandler to reiterate its Overweight rating and $328 price target, viewing the asset as a key future growth driver that will help mitigate the impact of Xgeva's eventual loss of exclusivity. This clinical success is further supported by the company's impressive 15.6% year-over-year revenue growth. However, a note of caution was raised regarding ocular adverse events observed in the trial, a risk factor that warrants monitoring. Separately, Amgen's obesity candidate, MariTide, showed promising Phase 2 efficacy with up to 20% average weight loss, but the market's reaction was mixed due to significant competitive pressures in the crowded obesity drug market. These developments, combined with stable corporate governance as confirmed by the recent shareholder meeting, highlight Amgen's strategic push to diversify and strengthen its late-stage pipeline, though challenges in execution and market competition remain.

Key Decisions for Investors

• Investors should view the positive Phase III bemarituzumab data as a significant de-risking event for the oncology pipeline, providing a crucial long-term growth driver to offset the future revenue loss from Xgeva's patent expiration.
• It is prudent to closely monitor the competitive landscape for the obesity treatment MariTide and seek further data on the ocular adverse events associated with bemarituzumab, as these factors will be critical to their ultimate commercial success.
• Given the strong 15.6% revenue growth, positive analyst ratings, and key pipeline advancements, investors may consider the current valuation an attractive entry point, while remaining mindful of the noted risks.